T2 Biosystems, Inc. revised revenue guidance for the fourth quarter ended December 31, 2017. Total revenue in the fourth quarter is expected to exceed the previously guided range of $1.1 to $1.3 million. The strength in the quarter is due to an increase in product revenue driven by demand for the T2Dx® Instrument and the T2Candida® Panel.